Biotech Daily

Monday June 30, 2025

Daily news on ASX-listed biotechnology companies

*** ASX UP, BIOTECH DOWN: PROTEOMICS UP 12%; CYNATA DOWN 12%**

*** VICTORIA $2.1m FOR CHILDHOOD CANCER**

*** TETRATHERIX UP 15% ON $25m TETRAMATRIX POLYMER IPO**

*** VITASORA UP-TO $4.6m TPAC PATIENT MONITORING DEAL**

*** TGA: 'NEW MEDICAL DEVICE REGULATIONS FOR PATIENT SAFETY'**

*** DIMERIX RECEIVES $4.2m FUSO MILESTONE**

*** OPTISCAN STARTS INVUE, INFORM BREAST CANCER STUDY**

*** MEMPHASYS FILES FELIX CE MARK APPLICATION**

*** LTR, APTAR COMPLETE 'EXTRACTABLES' STUDY FOR FDA FILING**

*** ACTINOGEN TAKES $14m ENDPOINTS RDTI LOAN**

*** ACTINOGEN: 100th PHASE IIb/III XANAMEM ALZHEIMER'S PATIENT**

*** BLINKLAB ETHICS APPROVAL FOR MAIN DX1 AUTISM STUDY**

*** CAMBIUM ETHICS APPROVAL FOR PHASE III ELATE OCULAR TRIAL**

*** PROTEOMICS GRANTED PROMARKER ENDO JAPAN PATENT**

*** OPYL CLARIFIES 'LOAN NOT SECURED AGAINST BITCOINS'**

*** EPSILON EGM 36% OPPOSE PRIOR ISSUE OF SHARES**

*** NAOS REDUCES TO 25.65% OF BTC**

*** PHILLIP ASSET DILUTED TO 9% OF ACRUX**

*** COPIA TAKES 5% OF BOTANIX**

*** POWERHOUSE BELOW 5% OF PERCHERON**

*** 'TWIGGY' FOREST, TATTARANG BELOW 5% OF EMYRIA**

*** DR ELIZABETH STONER REPLACES AROVELLA CHAIR DR THOMAS DUTHY**

*** QBIOTICS APPOINTS SERGIO DUCHINI DIRECTOR**

*** KOBE LI REPLACES EBR CO SEC BRENDAN CASE**

MARKET REPORT

The Australian stock market was up 0.33 percent on Monday June 30, 2025, with the ASX200 up 28.1 points to 8,542.3 points. Thirteen of the Biotech Daily Top 40 companies were up, 19 fell, seven traded unchanged and one was untraded. All four Big Caps rose.

Proteomics was the best, up 3.5 cents or 12.1 percent to 32.5 cents, with 442,679 shares traded. Optiscan climbed 10 percent; Impedimed and Micro-X improved more than six percent; Actinogen was up 4.55 percent; Aroa, Avita and Syntara were up more than three percent; CSL rose 2.2 percent; Botanix, Cochlear, Pro Medicus and Resmed were up one percent or more; with Clinuvel, Dimerix, Medical Developments and Mesoblast up by less than one percent.

Cynata led the falls, down two cents or 11.8 percent to 15 cents, with 787,826 shares traded. Amplia lost 9.1 percent; Curvebeam was down 7.8 percent; Atomo and Orthocell were down six percent or more; Alcidion, Genetic Signatures, Nova Eye, Paradigm and Prescient fell four percent or more; EBR and Emvision were down more than three percent; Cyclopharm and Starpharma shed more than two percent; Nanosonics and SDI were down more than one percent; with Clarity, Neuren and Telix down by less than one percent.

VICTORIA GOVERNMENT

The Victoria Government says it will provide $2.085 million to two researchers at Monash University and the Hudson Institute to develop treatments for children's cancers.
A media release from the Minister for Finance, Economic Growth and Jobs Danny Pearson said the funding was awarded under the Children's Cancer Colab's Next-Generation Therapies program to develop "new treatments for children's cancers that are the hardest to treat, including brain, bone and soft tissue cancers".
The Government said Monash University's Dr Iman Azimi would "develop models of medullo-blastoma, the most common paediatric brain tumor, to efficiently and accurately test potential treatments".
The Victoria Government said the Hudson Institute's Prof Ron Firestein would "receive funding to profile 50 additional paediatric cancer cell lines and using artificial intelligence will work to discover new treatments".
A spokesperson told Biotech Daily that Prof Firestein would receive $1,630,000 of the funding and Dr Azimi would receive $455,000.
The Government said that it had invested $35 million to establish the Children's Cancer Colab, along with $10 million from the Children's Cancer Foundation, which brought "together the best and brightest minds to undertake cutting-edge research to tackle childhood cancer".
The media release said the Next-Generation Therapies Program aimed "to develop cutting-edge therapies specifically for these paediatric cancers, to ensure survival rates continue to rise for young cancer patients".
Mr Pearson said fighting childhood cancer was "a battle no family should have to face, but it's a terrifying reality for hundreds of kids every year".
"This program will support our world-class researchers to deliver new life-saving treatments to give kids the best chance to grow up healthy and cancer-free," Mr Pearson said.

TETRATHERIX

Tetratherix opened up 15.3 percent at $3.32 following its $25 million initial public offer at $2.88 a share to list on the ASX and develop its polymer Tetramatrix technology.
The Sydney-based Tetratherix said it listed under the ticker code 'TTX' and had an indicative market capitalization of $145 million.
Earlier this month, the company said Tetramatrix was "the world's first bio-stealth fluid matrix and is being used to develop clinical products applicable across numerous areas including bone regeneration, tissue spacing and tissue healing" (BD: Jun 6, 2025).
At that time, Tetratherix said its chief executive officer was Will Knox and the chief financial officer was Cherie Beach, with founders chief technology officer Dr Ali Fathi, who invented the core technology and chief operating officer Terence Abrams.
Tetratherix said it would use the funds for a manufacturing facility and to commercialize its products in the US.
Tetratherix fell as low as $2.88 before closing up 14 cents or 4.9 percent at $3.02 with 715,245 shares traded.

VITASORA HEALTH (FORMERLY RESPIRI, ISONEA, KARMELSONIX)

Vitasora says it has a $US3 million ($A4.6 million) a year deal with The Physician Alliance Corporation (TPAC) for remote patient monitoring.
Vitasora said following a fee-for-service pilot program with the Baton Rouge, Louisiana-based TPAC earlier this year, Vitasora subsidiary Respiri Management signed a further multi-year agreement for the use of its remote patient monitoring system.
The company said TPAC was "a leading accountable care organization in the US" and had adopted its remote patient monitoring system "with expansion potential up-to its full panel of 15,000 Medicare patients under a per member per month, value-based and performance-linked agreement".
Vitasora said it would receive per member per month healthcare coordination fee across TPAC approved lives, fee-for-service for reimbursed remote patient monitoring services of $US70 per patient per month, with a 30 percent target patient conversion rate.
The company said it would receive a share of accountable care organization-attributed quality savings, scaling with accountable care organization growth and performance under US Centers for Medicare and Medicaid Services (CMS) value-based care metrics.
Vitasora said it expected to receive "up-to $US5 per member per month under the expanded agreement, taking into account [per member per month] fees and assuming the company is entitled to receive part of the quality savings".
The company said the agreement was effective from July 1, 2025 with an initial one-year term and automatic annual renewals.
Vitasora chief executive officer Marjan Mikel said the agreement with TPAC was "a pivotal moment for Vitasora".
"It represents validation not only of our business model but our ability to execute and scale complex value-based care solutions with speed and precision," Mr Mikel said.
"We are proud to be partnering with such an innovative and fast-growing organization and see this as just the beginning," Mr Mikel said.
"With CMS pushing for these models nationally, and with the results we've demonstrated, we are confident this contract is a blueprint for more to come," Mr Mikel said.
Separately, Vitasora had requested a trading halt "pending an announcement by the company to the market regarding a capital raising".
Trading will resume on July 2, 2025, or on an earlier announcement.
Vitasora last traded at 3.9 cents.

AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION

The Therapeutic Goods Administration says the Federal Government has introduced regulatory changes for medical devices to improve patient safety.

A media release from the TGA said hospitals would be required to report medical device adverse events, manufacturers supplying medical devices must use barcodes to identify their products and it will introduce “improved and clearer national recall processes”.

The TGA said mandatory reporting of medical device-related injuries or suspected injuries would begin on March 21, 2026 for all public, private and day hospitals.

The Administration said the reports would help it “to detect safety issues and prioritize patient safety”.

The TGA said the Australian Commission on Safety and Quality in Health Care would support the change by introducing “these new reporting requirements into hospital accreditation standards from 2030”.

The Administration said it would introduce a unique device identification (UDI) system for manufacturers supplying medical devices in Australia.

The TGA said under the changes manufacturers “must use barcodes to identify their products on all packaging and labelling and submit this data to the TGA”.

The Administration said mandatory compliance with the UDI system for implanted devices would begin in July 2026.

The TGA said “when used by healthcare organizations, UDI information can be integrated into hospital systems and patient records, including Myhealth Record, to accurately identify the specific medical device used”.

The Administration said it would “also maintain a public database of UDI information, giving patients access to details about their medical device”.

The TGA said the final change was “improved and clearer national recall processes”.

The Administration said it had begun “a stronger and more transparent process for recalling therapeutic goods in Australia … making it easier for suppliers and users to initiate and report product safety actions and assisting the TGA in responding quickly and appropriately”.

The TGA said “key improvements include new and simplified terminology, streamlined processes, enhanced legislative recall powers for the TGA and clearer communication of recall information for patients, healthcare professionals and users”.

The Administration said Australians who relied on medical devices would “benefit from the measures … to enhance the identification and management of device-related safety concerns”.

The TGA said it would “receive clearer identification and more detailed information about devices, allowing it to respond more quickly as and when issues are found”.

The Administration said the changes reinforced “the Government’s commitment to putting patients first when it comes to the safety and performance of medical devices”

TGA chief medical officer Prof Anthony Lawler said the administration welcomed the additional data that hospitals would be required to provide.

“This enhanced reporting will play a critical role in helping the TGA to identify potential safety concerns earlier,” Prof Lawler said.

“By identifying these signals sooner, we can act quickly and appropriately to protect the health and safety of all Australians,” Prof Lawler said.

TGA chief medical advisor Prof Robyn Langham said he encouraged “all healthcare facilities, surgeons and [general practitioners] to explore the powerful capabilities of UDI and the valuable opportunities it presents for enhancing patient care and clinical data systems”.

DIMERIX

Dimerix says it has received the first Fuso milestone payment of JPY400 million ($A4.2 million) for opening a DMX200 for FSGS phase III trial site in Japan.

Earlier this year, Dimerix said it would receive up-to $107 million to licence DMX-200 for focal segmental glomerulo-sclerosis (FSGS) in Japan to Osaka's Fuso Pharmaceuticals, including $104.1 million in milestones (BD: Jan 19, 2025).

Today, Dimerix said it had received the funds, with the site opening in Japan to "aid recruitment of … [the] clinical trial, with approximately 20 patients to be recruited to support potential approval in Japan".

The company said it could receive a further up-to JPY3,000 million in potential development milestones, up-to JPY6,800 million in potential sales milestones and tiered royalties from 15-to-20 percent of DMX2000 net sales in Japan.

Dimerix said it was pursuing licencing opportunities in other territories including China.

Dimerix was up half a cent or 0.9 percent to 57.5 cents with 3.8 million shares traded.

OPTISCAN IMAGING

Optiscan says it has begun a 50-patient study of its Invue in-vivo and Inform ex-vivo imaging devices for the assessment of breast cancer margins after surgery.

Last year, Optiscan said it had released its Invue microscope for providing "real-time, digital pathology access" to surgeons during surgery, and that the device could be used in cancer diagnosis and treatment (BD: Jun 4, Jul 15, 2024).

Earlier this year, Optiscan said it had a developed Inform, a "microscopic medical imaging device", for use in laboratory medicine, pathology practices, point-of-care and digital pathology (BD: Feb 19, 2025).

Today, the company said the study data from the Royal Melbourne Hospital would be used for US Food and Drug Administration regulatory submissions for both devices.

Optiscan said the study would research the clinical workflow and real-time imaging capabilities of both devices to assess breast cancer margins following lumpectomy.

The company said the study would use Invue during surgery "to capture in-vivo live imaging data from the surgical cavity after tumor removal, providing immediate feedback on tumor clearance".

Optiscan said resected tissue would then "be further examined with Inform ex-vivo outside the body with topical dyes which will provide additional data on imaging and pathology workflows to complement in vivo imaging and build further data for FDA submission for Optiscan's pathology device".

The company said the imaging data would be used for its artificial intelligence, machine learning algorithms currently in development.

Optiscan managing-director Prof Camile Farah said the company was "confident that the study, which will recruit 50 patients undergoing breast-conserving procedures, will demonstrate the capabilities of our Invue and Inform imaging devices".

"The significance of any proven capability to evaluate tumor margin with cellular-level precision during surgery coming out of the study cannot be over-estimated," Prof Farah said. "It has the potential to revolutionize breast cancer treatment, as real-time imaging opens the way for complete tumor removal to occur, while … preserving healthy tissue."

"While our Invue and Inform devices are designed to operate independently of each other, we have purposefully included both in this study to maximize the collection of data, minimize the need to recruit more patients and accelerate our regulatory submissions," Prof Farah said.

Optiscan was up one cent or 10 percent to 11 cents.

MEMPHASYS

Memphasys says it has submitted a Conformité Européenne (CE) mark regulatory dossier for approval to commercialize its Felix sperm separation device in Europe.

Last year, Memphasys said it would pursue CE mark for its Felix sperm separation device "as soon as practicable, following clinical trial completion" (BD: Oct 24, 2024).

Earlier this year, the company said its 104-couple trial with the Monash IVF Group of its Felix electrophoresis-based sperm separation device for use in in-vitro fertilization met its primary endpoint (BD: Mar 24, 2025).

In March, Memphasys managing-director Dr David Ali told Biotech Daily that Felix was not only not inferior to the swim-up technique it was statistically superior to density gradient centrifugation "the most common sperm preparation technique" ($p = 0.022$).

Today, the company said that following the completion of its clinical trial "this regulatory milestone reinforces the company's operational momentum … leadership and its determination to convert clinical innovation into commercial outcomes".

Dr Ali said submitting the CE mark application on schedule was a clear indicator the company was "delivering on the commercialization commitments made to investors".

"Our focus is to convert scientific innovation into near-term revenue and scaling into meaningful markets," Dr Ali said. "While Europe represents a significant future commercial opportunity for Felix, we are not waiting to commercialize in other regulatory markets."

"Felix can be sold in Japan, Canada, and New Zealand, and we are now gearing up to actively execute structured direct go-to-market plans in these markets," Dr Ali said.

Memphasys was unchanged at 0.5 cents with 8.6 million shares traded.

LTR PHARMA

LTR says with Chicago's Aptar Pharma it has completed 'extractables' studies and has begun 'leachables' studies for its Spontan intra-nasal spray for erectile dysfunction.

Last year, LTR said Aptar would co-develop and commercialize its Spontan nasal spray of vardenafil, marketed in the US as Levitra, for erectile dysfunction (BD: Aug 13, 2024).

Today, the company said the extractables study conducted with Aptar Pharma "evaluated the bottle and pump components of Spontan's container closure system".

LTR said the study "confirmed that all detected compounds were below [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] safety thresholds, the internationally recognized standards adopted by the [US Food and Drug Administration] … for pharmaceutical impurities".

The company said identified compounds would "be monitored in the … leachables study".

LTR said the FDA required extractables and leachables studies for all pharmaceutical products to ensure packaging materials do not compromise product safety or efficacy.

The company said for nasal spray products, these studies must meet specific regulatory thresholds due to direct tissue exposure and that the leachables study had begun under Aptar Pharma's management, evaluating the potential migration of the compounds from packaging into Spontan under real-world storage conditions.

LTR said Spontan used industry-standard bottle and pump components used in multiple FDA-approved nasal spray products and that the leachables study would take "at least 24 months to support shelf-life requirements".

The company said it could submit its FDA application once sufficient robust data was available, with study completion continuing post-approval as standard.

LTR said "with extractables complete and meeting safety thresholds, we continue progressing through the regulatory pathway".

LTR fell one cent or 3.3 percent to 29 cents with 1.3 million shares traded.

ACTINOGEN MEDICAL

Actinogen says it has an up-to $13.8 million loan from Sydney's Endpoints Capital against its expected Federal Research and Development Tax Incentives to 2027.
Actinogen said the interest rate would be "charged at commercial rates consistent with facilities of this nature".
The company said that it received an initial $3.0 million against its expected Research and Development Tax Incentive for the year to June 30, 2025, with $2.9 million to be made available on Australian Taxation Office approval of its recent advanced overseas finding.
Actinogen said it was eligible for up-to $7.9 million in relation to its forecast Research and Development Tax Incentive for the year to June 30, 2026.
Actinogen said the loan was repayable on "receipt of the rebate anticipated later in 2025".
The company said the funds were for its phase IIb/III Xanamem for Alzheimer's trial.
Actinogen was up 0.1 cents or 4.55 percent to 2.3 cents with 12.5 million shares traded.

ACTINOGEN MEDICAL

Actinogen says it has screened 100 of 220-patients in its phase IIb/III trial of Xanamem for Alzheimer's disease, triggering an interim safety and efficacy analysis.
Last year, Actinogen said it had treated the first of 220-patients in the phase IIb trial of its 10mg oral tablet Xanamem cortisol synthesis inhibitor; and later, said it treated the first US patient in the trial (BD: Apr 15, Dec 9, 2024).
Today, the company said the interim data analysis would be in late December 2025 following the 24-week visit of the one hundredth patient, with final results expected by 2027 and a second pivotal, phase III trial anticipated to begin by April 2027.
Actinogen said it believed "that fully enrolling the 220-planned participants will ensure that the safety and efficacy of oral Xanamem 10mg daily will be robustly demonstrated and as a result support the earliest possible regulatory approval of the drug".
The company said that it would meet with the US Food and Drug Administration before 2026 to discuss potential approval pathways for Xanamem for Alzheimer's disease, including expedited pathways should the … trial show "much stronger efficacy and safety than currently available treatments".

BLINKLAB

Blinklab says it has ethics approval to begin the 1,000-patient, main study phase of its US diagnostic trial of Dx1 for autism.
Last year, Blinklab said the US Food and Drug Administration had confirmed the study design and data requirements needed for 510(k) clearance of its Dx1 smartphone application autism diagnostic (BD: Dec 19, 2024).
At that time, the company said it would conduct an initial study of 100 children followed by a main study of 750-to-900 children with autism between two and 11 years of age.
Earlier this year, Blinklab said it opened the study at Dayton, Ohio's Primed Clinical Research and Chicago's North Shore Pediatric Therapy and enrolled 54 children in the study; and in May, said it had opened the main trial at Phoenix, Arizona's Southwest Autism Research and Resource Center (BD: Feb 5, 10, Apr 1, May 22, 2025).
Today, the company said the Princeton, New Jersey-based WIRB-Copernicus Group had granted it institutional review board approval for the trial.
Blinklab said it was "now finalizing logistics and contracts with additional clinical sites to initiate the main trial phase".
Blinklab was up 4.5 cents or 8.5 percent to 57.5 cents.

CAMBIUM BIO (FORMERLY REGENEUS)

Cambium says it has ethics approval for its 800-patient, phase III trial of Elate Ocular for moderate-to-severe dry eye disease in Australia and the US.

Earlier this year, Cambium said that it had met with the US Food and Drug Administration and agreed on the path for its Elate Ocular cell-based assay for severe dry eye disease (BD: Mar 18, 2025).

Today, the company said it had ethics approval from Adelaide's Bellberry Human Research Ethics Committee in Australia and Columbia, Maryland's Advarra Institutional Review Board in the US.

Cambium said it expected first patient dosing in October 2025, with top-line data expected by October 2026.

The company said the trial's co-primary endpoints were improvement in both signs, measured by total corneal fluorescein straining, and symptoms, measured by eye discomfort visual analogue scale (VAS) score, of dry eye disease.

Cambium chief executive officer Karolis Rosickas said ethics approval was "a critical step forward".

"We will now focus on site activation and operational readiness for first patient dosing in October 2025," Mr Rosickas said.

"This is a pivotal moment for Cambium Bio as we prepare to initiate the final stage of clinical development for our lead product," Mr Rosickas said.

Cambium was unchanged at 21 cents.

PROTEOMICS INTERNATIONAL LABORATORIES

Proteomics says the Japan Patent Office has granted it a first patent protecting its Promarker Endo diagnostic blood test for endometriosis.

Proteomics said the patent, titled 'Endometriosis Biomarkers' would protect its intellectual property in Japan until March 16, 2041.

The company said the "milestone patent is the first patent granted globally for Promarker Endo, further strengthening Proteomics International's growing [intellectual property] portfolio".

Proteomics said it had patent applications for Promarker Endo pending in Australia, Canada, China, Europe, India, Singapore, South Korea and the US.

Proteomics managing-director Dr Richard Lipscombe said the patent was "a significant achievement because it validates the novelty of Promarker Endo, our world-first blood test for endometriosis".

"Japan represents one of the largest and most advanced healthcare markets in the world," Dr Lipscombe said.

"Securing patent protection for our diagnostic technology in this region is a key step in our global commercialization pathway and provides a strong foundation for potential partnerships, licencing, and regulatory advancement," Dr Lipscombe said.

Proteomics was up 3.5 cents or 12.1 percent to 32.5 cents.

OPYL

Opyl says its $2,000,000 loan from director Anthony Guoga is "in fact, an unsecured obligation" and not secured against its Bitcoin holdings.

Last week, Opyl said it bought two Bitcoin for about $330,000 to be used to secure a $2,000,000 loan from Mr Guoga at 6.5 percent interest a year (BD: Jun 26, 2025).

Opyl was up 0.2 cents or 7.4 percent to 2.9 cents with 8.2 million shares traded.

EPSILON HEALTHCARE

Epsilon says its extraordinary general meeting has passed all resolutions but with up-to 35.83 percent against the ratification of the prior issue of shares.
Last month, Epsilon said shareholders would vote to ratify the prior issue of 45,000,000 shares, issue 100,000,000 warrants to its lenders, 10,000,000 and 25,000,000 warrants to chair Alan Beasley and managing-director Peter Giannopoulos as lenders as well as approve conversion rights of up-to 50,000,000 loan notes.
Today, the company said the ratification of the prior issue of shares had 53,287,671 votes (35.83%) in opposition, with 95,447,384 votes (64.17%) in support.
Epsilon said that the issue of 100,000,000 warrants to its lenders excluding Mr Beasley and Mr Giannopoulos was opposed by 53,525,369 votes (27.99%) with 137,690,911 votes (72.01%) in favor.
The company said the issue of warrants to Mr Beasley and Mr Giannopoulos as well as the conversion rights of the loan notes faced a similar number of votes against.
According to its most recent filing, Epsilon had 345,354,011 shares on issue, meaning that the 53,525,369 votes against the issue of warrants to lenders amounted to about 15.5 percent of the company, sufficient to requisition extraordinary general meetings.
Epsilon was in a suspension and last traded at 2.4 cents.

BTC HEALTH

Naos Asset Management Ltd says it has reduced its substantial shareholding in BTC from 86,897,697 shares (26.81%) to 83,427,758 shares (25.65%).
The Sydney-based Naos said that on June 25, 2025 it sold 3,469,939 shares for $181,803, or 5.2 cents a share.
BTC was up 0.1 cents or 1.7 percent to six cents.

ACRUX

Melbourne's Phillip Asset Management Ltd says its 37,561,419 share-holding in Acrux has been diluted from 10.32 percent to 9.21 percent due to the issue of shares.
Phillip Asset Management said it was diluted through the issue of shares from December 23, 2024 to May 23, 2025.
Last year, Acrux said it raised $1.34 million of a hoped-for $2 million in a share plan at 3.5 cents a share, taking the total to $4.0 million (BD: Dec 5, 2024; Jan 19, 2025).
Acrux fell 0.1 cents or 5.9 percent to 1.6 cents.

BOTANIX PHARMACEUTICALS

Copia Investment Partners Ltd says it has become a substantial shareholder in Botanix with 102,100,000 shares, or 5.21 percent.
The Melbourne-based Copia said that between February and June 2025 it bought 29,824,352 shares at prices ranging from 32 cents a share to 47.4 cents a share.
Botanix was up half a cent or 1.6 percent to 32 cents with 9.65 million shares traded.

PERCHERON THERAPEUTICS (FORMERLY ANTISENSE THERAPEUTICS)

The Brisbane-based Powerhouse Ventures Ltd says it has ceased its substantial shareholding in Percheron.
Powerhouse said that on June 26, 2025 it sold 6,459,495 shares for $78,502, or 1.2 cents a share.
Earlier this year, Powerhouse said it reduced its substantial shareholding in Percheron from 110,000,000 shares (10.12%) to 55,000,000 shares (5.06%) (BD: Apr 23, 2025).
According to its most recent notice, Percheron had 1,087,437,633 shares on issue, meaning that Powerhouse retained 4.46 percent of the company.
In February, Percheron said it had received a notice from Brisbane's Powerhouse Ventures calling for a vote to replace its board with Doran Eldar, Renerve managing-director Dr Julian Chick and Richard Hamersley (BD: Feb 25, 2025).
Later, the company said its second extraordinary general meeting had voted up-to 73.46 percent against the Powerhouse requisitioned removal of its board and the appointment of replacements (BD: Apr 28, 2025).
Percheron was unchanged at one cent with three million shares traded.

EMYRIA

Perth's Tattarang Ventures Pty Ltd says it has been diluted below the five percent substantial shareholder threshold in Emyria due to a placement on June 26, 2025.
In 2021, Emyria said it had raised $5 million at 25 cents a share from the Dr Andrew 'Twiggy' Forrest-controlled Tattarang (BD: Nov 22, 2021).
Earlier this month, the company said it had "firm bids" for a $4 million placement at 2.4 cents a share to fund its treatment programs (BD: Jun 18, 2025).
Last year, Tattarang said that, with Tenmile Ventures, the Peepingee Trust, Nicola Forrest and Dr Forrest, it increased and was diluted in Emyria from 20,000,000 shares (7.29%) to 23,817,777 shares (5.82%) (BD: May 10, 2024).
According to its most recent filing, Emyria had 611,451,030 shares on issue, meaning that Tattarang retained 3.895 percent of the company.
Emyria was up 0.1 cents or 3.7 percent to 2.8 cents with 6.3 million shares traded.

AROVELLA THERAPEUTICS

Arovella says non-executive director and chair Dr Thomas Duthy will be retiring, effective from July 1, 2025, with director Dr Elizabeth Stoner appointed interim chair.
Arovella said Dr Duthy had been chair since March 2023 and was retiring "to pursue new business opportunities".
The company said Dr Stoner had previously been interim chair of the company and would serve as interim chair again while it undertook "a thorough process to appoint a new chair".
Arovella managing-director Dr Michael Baker said the company thanked Dr Duthy for "his contributions to the company since 2023".
"The company is in a terrific position as it embarks on taking its lead [chimeric antigen receptor-invariant natural killer] T-cell therapy program into phase I," Dr Baker said.
"Arovella will seek an experienced individual to chair the company as we transition to clinical trials for our lead program ALA-101 and develop our solid tumor pipeline," Dr Baker said.
Arovella fell one cent or 9.1 percent to 10 cents with 2.4 million shares traded.

QBIOTICS GROUP

Qbiotics says it has appointed Sergio Duchini as a non-executive director, effective from July 1, 2025.

Qbiotics said Mr Duchini had more than 30 years of experience, had been chair of Lymphoma Australia, a director of Ausbiotech and a board member of Deloitte Australia and was currently chair of Neurizon, formerly Pharmaust, and a director of Enlitic.

According to his Linkedin page, Mr Duchini held a Bachelor of Commerce from the University of Melbourne.

Qbiotics is a public-unlisted company.

EBR SYSTEMS

EBR says it has appointed Kobe Li as its Australian company secretary, effective from today, to replace Brendan case who has resigned.

EBR said Mr Li had “previously worked at the ASX as a senior advisor in the listings compliance team and is a member of the Governance Institute of Australia”.

EBR fell four cents or 3.2 percent to $1.195 with 1.3 million shares traded.